News
-
-
PRESS RELEASE
Sandoz confirms regulatory approval for new semaglutide treatment option in Brazil, paving way to expand patient access
Sandoz receives regulatory approval for Owozy®, a new semaglutide treatment for type-2 diabetes in Brazil, enhancing patient access and supporting local healthcare systems -
-
PRESS RELEASE
Sandoz announces key leadership changes
Sandoz announces key leadership changes: Pascal Bouye appointed President, Generics Manufacturing & Supply; Glenn Gerecke takes on new role within the company. Keren Haruvi to oversee global M&A activities. Simon Goeller appointed Country President, Germany -
-
-
-
-
-
PRESS RELEASE
Sandoz steps up in-house biosimilar capabilities, opening state-of-the-art development centre to capture ‘golden decade’ opportunity
Sandoz opens new biosimilar development centre in Ljubljana, Slovenia, to enhance in-house capabilities for upcoming biologic patent expiries. The state-of-the-art facility will support growth in the 'golden decade' of healthcare
